Exclusive deals struck between insurance companies and pharmacies are increasingly drawing scrutiny from patients, pharmacists and cabinet ministers. The arrangements, known as preferred pharmacy networks (PPNs), are meant to deal with rising prices of pharmaceutical drugs. But detractors say these plans mean less transparency, competition and consumer choice.The Globe’s retailing reporter Susan Krashinsky Robertson and wealth management and insurance reporter Clare O’Hara explain why the blowback against PPNs is rooted in questions about who gets to approve treatment for patients.Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com